| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Aquestive Therapeutics, Inc.
13G/A
Amendment 5
AQST · 03843E104
|
0.6% |
10/7/2026
Event 10/7/2026
|
|||
| Bratton Douglas K | 0.6% | ||||
| MonoLine RX II, L.P. | 0% | ||||
| MonoLine RX III, L.P. | 0% | ||||
| MonoLine RX, L.P. | 0% | ||||
| MonoLine Partners, L.P. | 0% | ||||
| MonoSol Rx Genpar, L.P. | 0% | ||||
| Bratton Capital Management, L.P. | 0.3% | ||||
| Bratton Capital Inc. | 0.3% | ||||
| Bratton Family Partners L.P. | 0% | ||||
|
Aquestive Therapeutics, Inc.
13G/A
Amendment 4
AQST · 03843E104
|
11.1% |
2/13/2025
Event 12/31/2024
|
|||
| Bratton Douglas K | 11.1% | ||||
| MonoLine RX II, L.P. | 3.8% | ||||
| MonoLine RX III, L.P. | 2.9% | ||||
| MonoLine RX, L.P. | 1.9% | ||||
| MonoLine Partners, L.P. | 2.1% | ||||
| MonoSol Rx Genpar, L.P. | 0.1% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.